Firstface Co., Ltd. v. Apple, Inc.

District Court, N.D. California·Decided June 15, 2022·No. 3:18-cv-02245·Unknown

Opinion

FIRSTFACE CO., LTD., Case No. 3:18-cv-02245-JD

Plaintiff, CLAIM CONSTRUCTION ORDER v. Re: Dkt. No. 61 Defendant.

The parties in this patent infringement action seek construction of eight phrases from the asserted claims in U.S. Patent No. 9,633,373 (the ’373 patent) and U.S. Patent No. 9,779,419 (the ’419 patent).1 The Court received full briefing from the parties and held a technology tutorial. During the technology tutorial, defendant Apple made a comment to the effect that plaintiff Firstface had asserted inconsistent construction positions before the Patent Trial and Appeal Board. The Court invited each side to file a ten-page supplemental brief on the issue. Dkt. No. 118. Apple chose to file almost 900 pages of materials that ranged far beyond PTAB proceedings. Dkt. No. 123. The Court ordered this improper and massively oversized filing to be stricken from the docket, and allowed the parties to file the ten-page submissions as originally contemplated. See Dkt. Nos. 192 (strike order), 130 (Apple), 131 (Firstface). 1 The parties’ briefing on claim construction also included terms from U.S. Patent No. 8,831,557 (the ’557 patent). See, e.g., Dkt. No. 61. All asserted claims of the ’557 patent, and some of the asserted claims of the ’373 and ’419 patents were found unpatentable in inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB). Dkt. No. 106. The final written Firstface asserts claims 11-14 and 18 of the ’373 patent and claims 10-13 and 15-17 of the ’419 patent against Apple. Dkt. No. 1 at ¶¶24, 37; Dkt. No. 106 at 2. The ’373 patent and ’419 patent are both continuations of the same application and share a common specification. See Dkt. No. 61-3; Dkt. No. 61-4. The patents describe a mobile communication terminal and method for operating the mobile communication terminal that allows for simultaneous activation of the display screen and user authentication. Dkt. No. 61-3 at 1:17-23. The prior art required a separation of these functions, requiring that the device be activated first and then requiring a second input to authenticate the user. Id. at 25-49. The activation button may also be used to perform multiple functions if the button is pressed multiple times or for a longer period of time. Id. at 4:51-5:2. The ’373 patent and ’419 patent primarily differ in the specificity of their claims; the ’373 patent’s claims are more general with regard to their claiming of the functions of the activation button while the ’419 patent claims the use of fingerprint recognition and authentication specifically as a function of the activation button. Compare Dkt. No. 61-3 at 14:14-57 with Dkt. No. 61-4 at 14:15-65. Claim construction analysis “‘must begin and remain centered on the claim language itself, for that is the language the patentee has chosen to particularly point[] out and distinctly claim[] the subject matter which the patentee regards as his invention.’” Source Vagabond Sys. Ltd. v. Hydrapak, Inc., 753 F.3d 1291, 1299 (Fed. Cir. 2014) (quoting Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc., 381 F.3d 1111, 1116 (Fed. Cir. 2004)). Claim terms are given their “ordinary and customary meaning,” which is “the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention.” Phillips v. AWH Corp., 415 F.3d 1303, 1312-13 (Fed. Cir. 2005) (en banc) (internal quotation omitted). “The subjective intent of the inventor when he used a particular term is of little or no probative weight in determining the scope of a claim (except as documented in the prosecution history).” Markman v. Westview “Rather the focus is on the objective test of what one of ordinary skill in the art at the time of the invention would have understood the term to mean.” Markman, 52 F.3d at 986. The parties do not dispute the definition of a person of ordinary skill in the art. As the Federal Circuit has underscored, the “only meaning that matters in claim construction is the meaning in the context of the patent.” Trustees of Columbia Univ. v. Symantec Corp., 811 F.3d 1359, 1363 (Fed. Cir. 2016). The presumption that plain and ordinary meaning can be overcome only by a patentee’s express definition of a term or express disavowal of the scope of the claim has been clarified. Id. at 1364. A term may be redefined “by implication” when given a meaning that is ascertainable from a reading of the specification or the patent documents. Id. Redefinition and disavowal need not be expressly stated or called out in haec verba. Id. at 1363. “The ordinary meaning of a claim term is not the meaning of the term in the abstract,” but the term’s “meaning to the ordinary artisan after reading the entire patent.” Astra Zeneca AB v. Mylan Pharm. Inc., 19 F.4th 1325, 1330 (Fed. Cir. 2021) (quotations omitted) (quoting Eon Corp. IP Holdings v. Silver Spring Networks, 815 F.3d 1314, 1320 (Fed. Cir. 2016)). With this teaching, the rule that a claim and its constituent words and phrases are interpreted in light of the intrinsic evidence flourishes anew. The touchstones are the claims themselves, the specification and, if in evidence, the prosecution history. Phillips, 415 F.3d at 1312-17. This intrinsic evidence is the most significant source of the legally operative meaning of disputed claim language. Continental Circuits LLC v. Intel Corp., 915 F.3d 788, 799 (Fed. Cir. 2019). The claim language can “provide substantial guidance as to the meaning of particular claim terms,” both through the context in which the claim terms are used and by considering other claims in the same patent. Phillips, 415 F.3d at 1314. The specification is also a crucial source of information: although it is improper to read limitations from the specification into the claims, the specification is “the single best guide to the meaning of a disputed term.” Id. at 1315 (“[T]he specification ‘is always highly relevant to the claim construction analysis. Usually, it is dispositive . . .’”) (internal quotations omitted); see also Merck & Co., Inc. v. Teva Pharms. USA, Inc., 347 F.3d 1367, 1370 (Fed. Cir. 2003) (“[C]laims must be construed so as to be consistent treatises) to resolve the scope and meaning of a claim when circumstances warrant that. Phillips, 415 F.3d at 1317. A. “inactive state”/ “while the touch screen display is turned off” (’373 patent claims 11-12; ’419 patent claims 10, 12, 16-17) Firstface’s Proposed Apple’s Proposed Court’s Construction Construction Construction “a state in which the display is “state in which the display is “a state in which the device is turned off yet the device itself not receiving power” communicable but a display is turned on” screen is turned off” The term “inactive state” is expressly defined in the shared specification of the ’373 and ’419 patents. “The term ‘inactive state’ used herein refers to a state in which the mobile communication terminal is communicable but a display screen is turned off.” Dkt. No. 61-32 at 3:21-23. It is a core principle of claim construction that the patentee may act as his own lexicographer if the specification defines a term “with reasonably clarity, deliberateness, and precision.” Abbott Labs. v. Syntron Bioresea

Free access — add to your briefcase to read the full text and ask questions with AI

Firstface Co., Ltd. v. Apple, Inc., (N.D. Cal. 2022).

Firstface Co., Ltd. v. Apple, Inc. (Firstface Co., Ltd. v. Apple, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Thorner v. Sony Computer Entertainment America LLC
669 F.3d 1362 (Federal Circuit, 2012)
O.I. Corporation v. Tekmar Company Incorporated
115 F.3d 1576 (Federal Circuit, 1997)
Starhome Gmbh v. AT & T Mobility LLC
743 F.3d 849 (Federal Circuit, 2014)
Source Vagabond Systems Ltd. v. Hydrapak, Inc.
753 F.3d 1291 (Federal Circuit, 2014)
Hill-Rom Services, Inc. v. Stryker Corporation
755 F.3d 1367 (Federal Circuit, 2014)
Trustees of Columbia Univ. v. Symantec Corporation
811 F.3d 1359 (Federal Circuit, 2016)
Continental Circuits LLC v. Intel Corporation
915 F.3d 788 (Federal Circuit, 2019)
Astrazeneca Ab v. Mylan Pharmaceuticals Inc.
19 F.4th 1325 (Federal Circuit, 2021)